BG
AKBA icon

Baupost Group’s Akebia Therapeutics AKBA Stock Holding History

Baupost Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-15,000,000
Closed -$204M – 38
2020
Q2 		$204M Sell
15,000,000
-2,527,968
-14% -$26.2M 2.54% 12
2020
Q1 		$133M Sell
17,527,968
-2,043,485
-10% -$15.9M 1.96% 15
2019
Q4 		$124M Sell
19,571,453
-4,900,000
-20% -$23.3M 1.37% 21
2019
Q3 		$95.9M Hold
24,471,453
– – 1.09% 24
2019
Q2 		$118M Hold
24,471,453
– – 1.07% 24
2019
Q1 		$200M Hold
24,471,453
– – 1.68% 22
2018
Q4 		$135M Buy
+24,471,453
New +$192M 1.17% 20

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Baupost Group's AKBA Position: Q3 2020 in Review

Baupost Group sold out of Akebia Therapeutics (AKBA) in Q3 2020, closing a stake of 15,000,000 shares — an estimated $204M sold.

Baupost Group first reported a position in AKBA in Q4 2018 and held it in 7 quarters. The position peaked at $204M in Q2 2020. 164 funds tracked by Wall St. Rank hold AKBA as of Q3 2020.

  • Baupost Group reported no remaining Akebia Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Baupost Group sold 15,000,000 Akebia Therapeutics shares in Q3 2020, an estimated $204M.
  • Baupost Group first reported a position in Akebia Therapeutics in Q4 2018 and held it in 7 quarters.
  • Baupost Group's Akebia Therapeutics position peaked at $204M in Q2 2020.
  • 164 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2020.

Based on Baupost Group's 13F filing for Q3 2020, filed 13 Nov 2020.